$IMRX· SEC filing ·

IMRX Reports 64% 12M OS in Pancreatic Cancer, $217M Cash Runway to 2029, MAPKeeper 301 Phase 3 2026

Immuneering Corporation Class A Common Stock · PHARMACEUTICAL PREPARATIONS · Now $4.49

Post-detection moves

1h
1d
3d
7d
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS